Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway

Wang,Xingxing; Gui,Lu; Zhang,Youyuan; Zhang,Jihong; Shi,Jimin; Xu,Guoxiong

doi:10.3892/ijo.2014.2261

Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway

Authors:
- Xingxing Wang
- Lu Gui
- Youyuan Zhang
- Jihong Zhang
- Jimin Shi
- Guoxiong Xu
View Affiliations

Affiliations: Center Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: January 21, 2014 https://doi.org/10.3892/ijo.2014.2261
Pages: 1099-1106
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced ovarian cancer is a devastating disease. Gaining biomarkers of early detection during ovarian tumorigenesis may lead to earlier diagnosis and better therapeutic strategies. Cystatin B (CSTB) functions as an inhibitor to suppress intracellular cysteine proteases and has been implicated in several types of cancers. The present study explored the expression of CSTB in human ovarian tumors, to investigate CSTB expression associated with clinicopathological features, and to examine the effect of transforming growth factor-β (TGF-β), which plays a key role in ovarian tumorigenesis, on CSTB expression in ovarian cancer cells. The ovarian tissue samples from 33 patients were retrieved. The expression of CSTB in ovarian tissue was examined by immunohistochemistry. We found that CSTB was overexpressed in human ovarian surface epithelial tumors, including serous, mucinous and clear cell tumors. The immunoreactive staining of CSTB was strong in borderline and malignant tumors, weak in benign tumors, and negative in normal tissue counterparts, but was not correlated with the clinicopathological features of patients with ovarian tumors, such as age, histological types, tumor size, lymph node metastasis and clinical stages. The CSTB at mRNA and protein levels in two types of epithelial ovarian cancer cells, OVCAR-3 and SK-OV-3, was decreased after TGF-β1 treatment detected by quantitative PCR and western blot analysis, respectively. The inhibitory effect of TGF-β1 on CSTB expression was abolished in the presence of SB-431542, a TGF-β type I receptor kinase inhibitor. Our data suggest that CSTB is tumor tissue-specific and overexpressed in ovarian borderline and malignant tumors. The increased CSTB expression in ovarian tissue represents tumor progression and is dysregulated by the TGF-β signaling pathway. CSTB may become a novel diagnostic intracellular biomarker for the early detection of ovarian cancer.

View Figures

View References

1.	Rauh-Hain JA, Krivak TC, Del Carmen MG and Olawaiye AB: Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 4:15–21. 2011.PubMed/NCBI
2.	Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 22:255–288. 2001.PubMed/NCBI
3.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
4.	Sankaranarayanan R and Ferlay J: Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 20:207–225. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Burger HG, Fuller PJ, Chu S, et al: The inhibins and ovarian cancer. Mol Cell Endocrinol. 180:145–148. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar
7.	Jelovac D and Armstrong DK: Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des. 18:3812–3815. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Van Nagell JR Jr and Pavlik EJ: Ovarian cancer screening. Clin Obstet Gynecol. 55:43–51. 2012.
9.	Prat J, Ribe A and Gallardo A: Hereditary ovarian cancer. Hum Pathol. 36:861–870. 2005. View Article : Google Scholar
10.	Turk V, Stoka V and Turk D: Cystatins: biochemical and structural properties, and medical relevance. Front Biosci. 13:5406–5420. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Smid L, Strojan P, Budihna M, et al: Prognostic value of cathepsins B, D and steffins A and B in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 254(Suppl 1): S150–S153. 1997. View Article : Google Scholar : PubMed/NCBI
12.	Kos J and Lah TT: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (Review). Oncol Rep. 5:1349–1361. 1998.PubMed/NCBI
13.	Levicar N, Kos J, Blejec A, et al: Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detect Prev. 26:42–49. 2002. View Article : Google Scholar
14.	Zhang R, Tremblay TL, McDermid A, Thibault P and Stanimirovic D: Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia. 42:194–208. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Strojan P, Anicin A, Svetic B, Pohar M, Smid L and Kos J: Stefin A and stefin B: markers for prognosis in operable squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 68:1335–1341. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Shiraishi T, Mori M, Tanaka S, Sugimachi K and Akiyoshi T: Identification of cystatin B in human esophageal carcinoma, using differential displays in which the gene expression is related to lymph-node metastasis. Int J Cancer. 79:175–178. 1998. View Article : Google Scholar
17.	Ebert E, Werle B, Julke B, et al: Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol. 421:259–265. 1997. View Article : Google Scholar : PubMed/NCBI
18.	Ji NY, Kang YH, Park MY, et al: Development of a fluorescent microsphere immunoassay for cystatin B (CSTB) in serum of patients with hepatocellular carcinoma. Clin Chem Lab Med. 49:151–155. 2011.PubMed/NCBI
19.	Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brunner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res. 6:505–511. 2000.PubMed/NCBI
20.	Mirtti T, Alanen K, Kallajoki M, Rinne A and Soderstrom KO: Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Prostate. 54:290–298. 2003. View Article : Google Scholar : PubMed/NCBI
21.	Massague J: TGFbeta in cancer. Cell. 134:215–230. 2008. View Article : Google Scholar
22.	Nilsson EE and Skinner MK: Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod Biomed Online. 5:254–258. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Attisano L and Wrana JL: Signal transduction by the TGF-beta superfamily. Science. 296:1646–1647. 2002. View Article : Google Scholar : PubMed/NCBI
24.	Derynck R, Zhang Y and Feng XH: Smads: transcriptional activators of TGF-beta responses. Cell. 95:737–740. 1998. View Article : Google Scholar : PubMed/NCBI
25.	Massague J, Seoane J and Wotton D: Smad transcription factors. Genes Dev. 19:2783–2810. 2005. View Article : Google Scholar
26.	Cardillo MR, Yap E and Castagna G: Molecular genetic analysis of TGF-beta1 in ovarian neoplasia. J Exp Clin Cancer Res. 16:49–56. 1997.PubMed/NCBI
27.	Wang D, Kanuma T, Mizunuma H, et al: Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res. 60:4507–4512. 2000.PubMed/NCBI
28.	Berchuck A, Rodriguez G, Olt G, et al: Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol. 166:676–684. 1992. View Article : Google Scholar : PubMed/NCBI
29.	Zeng F, Xu G, Zhou T, et al: Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression. Med Oncol. 29:2519–2526. 2012. View Article : Google Scholar : PubMed/NCBI
30.	Inman GJ, Nicolas FJ, Callahan JF, et al: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 62:65–74. 2002. View Article : Google Scholar : PubMed/NCBI
31.	Lah TT, Kokalj-Kunovar M, Kastelic L, et al: Cystatins and stefins in ascites fluid from ovarian carcinoma. Cancer Lett. 61:243–253. 1992. View Article : Google Scholar : PubMed/NCBI
32.	Kastelic L, Turk B, Kopitar-Jerala N, et al: Stefin B, the major low molecular weight inhibitor in ovarian carcinoma. Cancer Lett. 82:81–88. 1994. View Article : Google Scholar : PubMed/NCBI
33.	Pennacchio LA, Lehesjoki AE, Stone NE, et al: Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science. 271:1731–1734. 1996. View Article : Google Scholar : PubMed/NCBI
34.	Kaur G, Mohan P, Pawlik M, et al: Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy. Am J Pathol. 177:2256–2267. 2010. View Article : Google Scholar : PubMed/NCBI
35.	Butinar M, Prebanda MT, Rajkovic J, et al: Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model. Oncogene. Aug 19–2013.Epub ahead of print. View Article : Google Scholar
36.	Feldman AS, Banyard J, Wu CL, McDougal WS and Zetter BR: Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 15:1024–1031. 2009. View Article : Google Scholar : PubMed/NCBI
37.	Gashenko EA, Lebedeva VA, Brak IV, Tsykalenko EA, Vinokurova GV and Korolenko TA: Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer. Int J Circumpolar Health. 72:212152013. View Article : Google Scholar : PubMed/NCBI
38.	Wong AS and Leung PC: Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res. 33:3–16. 2007. View Article : Google Scholar : PubMed/NCBI
39.	Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol. 11:S44–S51. 2001.PubMed/NCBI
40.	Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
41.	Lynch MA, Nakashima R, Song H, et al: Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res. 58:4227–4232. 1998.PubMed/NCBI
42.	Chen T, Triplett J, Dehner B, et al: Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res. 61:4679–4682. 2001.PubMed/NCBI